Loading organizations...
Celularity has raised $250.0M across 1 funding round.
Key people at Celularity.
Celularity has raised $250.0M in total across 1 funding round.
Celularity is a publicly traded biotechnology company based in Florham Park, New Jersey, that develops off-the-shelf allogeneic cell therapies and biomaterial products derived from postpartum placentas. Founded in 2017 as an Anthrogenesis spinout by Robert Hariri, the firm targets cancer, degenerative conditions, and immune disorders using natural killer cells, CAR T cells, and mesenchymal-like adherent stromal cells. The enterprise operates a 150,000 square foot manufacturing facility staffed by over 100 scientists and engineers to support more than 15 clinical trials. Celularity recently secured a $35 million strategic licensing deal for its biomaterials portfolio while retaining exclusive manufacturing rights, and generated $12.2 million from selling state net operating losses. To advance its regenerative medicine pipeline, the company is backed by notable investors including Sorrento Therapeutics, United Therapeutics, Human Longevity, Tony Robbins, and the Genting Group.
Celularity Inc. (NASDAQ: CELU) is a regenerative and cellular medicine company developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies sourced from the postpartum placenta.[1][2][4] It targets aging-related diseases like degenerative conditions, cancer, and immune disorders using mesenchymal-like adherent stromal cells (MLASCs), CAR T-cells, and natural killer (NK) cells, while also offering products like Biovance®, a decellularized amniotic membrane for wound healing.[1][4] Celularity serves patients and healthcare providers needing off-the-shelf, scalable therapies, addressing unmet needs for accessible, affordable cellular medicines through its integrated manufacturing platform.[1][2]
The company has achieved growth momentum via commercial biomaterial sales, including an exclusive distribution deal for Halal-certified products in over 100 countries, and recent R&D advances like DDHAM-3L technology for ocular surface reconstruction published in 2025.[2][4] Its 150,000 sq ft GMP-capable facility supports clinical-scale production, positioning it to scale both therapeutics and biomaterials.[1]
Celularity was founded by Robert Hariri, MD, PhD, based on his pioneering research into placenta-derived cellular therapeutics and biomaterials, emerging as a spin-up and roll-up of technologies from partners like Sorrento Therapeutics (antibody-CAR constructs) and Human Longevity (IP and stem cell sequencing).[3][5] Hariri, now Chairman and CEO, launched the company with substantial backing, including a $250M raise from billionaire investors, starting as a mature operation with labs, manufacturing, and licenses already in place.[3]
Peter H. Diamandis, MD, serves as Co-Founder and Vice Chairman alongside Hariri, bringing expertise in longevity and innovation.[5] Early traction came from consolidating underfunded assets in immunotherapy and regeneration, with a focus on disrupting the field using placental stem cells; pivotal moments include building a diversified portfolio from a single placenta source and going public via NASDAQ.[1][3][4]
Celularity rides the wave of regenerative medicine and cellular immunotherapy, capitalizing on timing for placenta-based "off-the-shelf" solutions amid demand for scalable alternatives to personalized therapies.[1][3] Market forces like rising aging populations, cancer prevalence, and needs for affordable biologics favor its approach, as placental tissue offers abundant, ethically sourced material without donor matching issues.[1][4]
It influences the ecosystem by pioneering biomaterials for applications like ocular reconstruction and wound healing, expanding into Halal-certified global markets, and consolidating fragmented tech in immunotherapy—potentially disrupting incumbents while enabling surgeons with regenerative tools.[2][3][4]
Celularity is primed to advance its biomaterial ramp-up and prioritize next-gen placental cell therapies, with 2023 strategic reviews signaling pipeline focus on high-impact candidates like NK cells and CAR T for cancer and degeneration.[4] Trends in iPSC integration, immunotherapy scale-up, and longevity biotech will shape its path, potentially via more partnerships and consolidations of undercapitalized assets.[2][3]
Its influence may evolve as the leader in placenta-derived medicines, delivering accessible therapies that "disrupt the disruptors" and consolidate regeneration tools, fulfilling its mission to address global unmet needs from the "most biocreative event on earth."[1][3]
Celularity has raised $250.0M in total across 1 funding round.
Celularity's investors include Balderton Capital, Bold Capital Partners, Section 32, Version One Ventures, Dylan Taylor, Michael Dell.
Key people at Celularity.
Celularity has raised $250.0M across 1 funding round. Most recently, it raised $250.0M Series U in February 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2018 | $250.0M Series U | Balderton Capital, Bold Capital Partners, Section 32, Version One Ventures, Dylan Taylor, Michael Dell |